首页> 美国卫生研究院文献>other >Uroporphyrinogen Decarboxylase as a Potential Target for Specific Components of Traditional Chinese Medicine: A Virtual Screening and Molecular Dynamics Study
【2h】

Uroporphyrinogen Decarboxylase as a Potential Target for Specific Components of Traditional Chinese Medicine: A Virtual Screening and Molecular Dynamics Study

机译:尿卟啉原脱羧酶作为一个潜在的目标中国传统医药的具体组成部分:虚​​拟筛选和分子动力学模拟研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Uroporphyrinogen decarboxylase (UROD) has been suggested as a protectant against radiation for head and neck cancer (HNC). In this study, we employed traditional Chinese medicine (TCM) compounds from TCM () to screen for drug-like candidates with potential UROD inhibition characteristics using virtual screening techniques. Isopraeroside IV, scopolin, and nodakenin exhibited the highest Dock Scores, and were predicted to have good Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties. Two common moieties, 2H-chromen-2-one and glucoside, were observed among the top TCM candidates. Cross comparison of the docking poses indicated that candidates formed stable interactions with key binding and catalytic residues of UROD through these two moieties. The 2H-chromen-2-one moiety enabled pi-cation interactions with Arg37 and H-bonds with Tyr164. The glucoside moiety was involved in forming H-bonds with Arg37 and Asp86. From our computational results, we propose isopraeroside IV, scopolin, and nodakenin as ligands that might exhibit drug-like inhibitory effects on UROD. The glucoside and 2H-chromen-2-one moieties may potentially be used for designing inhibitors of UROD.
机译:尿卟啉原脱羧酶(UROD)已被建议作为头颈癌(HNC)的辐射防护剂。在这项研究中,我们使用了来自TCM()的中药(TCM)化合物,使用虚拟筛选技术筛选具有潜在UROD抑制特性的药物样候选物。异鸦胆苷IV,scopolin和Nodakenin表现出最高的Dock评分,并被预测具有良好的吸收,分布,代谢,排泄和毒性(ADMET)特性。在顶级中医候选药中观察到两个常见的部分,2H-chromen-2-one和葡萄糖苷。对接姿势的交叉比较表明,候选物通过这两个部分与UROD的关键结合和催化残基形成了稳定的相互作用。 2H-chromen-2-one部分可以使pi-阳离子与Arg37相互作用,并与Tyr164形成H键。葡糖苷部分参与与Arg37和Asp86形成H键。根据我们的计算结果,我们提出异iso草苷IV,scopolin和Nodakenin作为配体,可能对UROD表现出类似药物的抑制作用。葡糖苷和2H-色烯-2-酮部分可潜在地用于设计UROD抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号